Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced the addition of Scott A. Kelly, M.D., FAAPMR, to its board of directors, effective April 10, 2017. With this appointment, the company’s board of directors now includes eight members. “Scott is passionate about target-specific treatments and personalized medicine that improve the lives of patients,” Denis R. Burger, Ph.D., vice chairman and chief science officer of CytoDyn, stated in the news release. “He has been a supporter and significant investor in CytoDyn, and we look forward to his contributions to our Company as a member of our Board.” Kelly brings considerable industry experience to the CytoDyn board, having served at Atlanta-based Resurgens Orthopaedics since 2002. Among his achievements during this tenure, Kelly has held the positions of Director of the Safety Council since 2013 and Medical Director of the Rusurgens Orthopaedics’ Spine Center since 2007. In 2016 and 2017, Kelly was named among America’s Best Physicians by The National Consumer Advisory Board, and he has received “Top Doctor” classification numerous times from such publications as Castle Connolly (2015, 2016 and 2017) and Atlanta Magazine (2016).
To view the full press release, visit http://nnw.fm/1gV7Z
About CytoDyn
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven phase 1 and phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the company, please visit www.cytodyn.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
